首页> 外文期刊>Journal of medical ethics >When does an advantage become unfair? Empirical and normative concerns in Semenya’s case
【24h】

When does an advantage become unfair? Empirical and normative concerns in Semenya’s case

机译:什么时候有利地变得不公平? Semenya案例中的经验和规范性问题

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

There is a fundamental tension in many sports: human sex is not binary, but there are only two categories in which people can compete: male and female. Over the past 10 years, the International Association of Athletics Federations (IAAF) regulations have been at the centre of two notable legal disputes. The Court of Arbitration for Sport (CAS) reached two contradictory rulings: in the first case (Dutee Chand vs Athletics Federation India and IAAF), the IAAF regulations for the eligibility of athletes to compete in the female category were suspended (24 July 2015) on grounds of "discrimination against the female category"; in the latter (Caster Semenya and Athletics South Africa vs IAAF), the regulations were reaffirmed (1 May 2019) on grounds that although discriminatory, they are necessary to maintain a "level playing field" and to “protect” the female category. Although Semenya’s case has paved the way for questioning existing gender norms in sport, a new stable norm has yet to emerge from her case. The pharmacological solution put forward by IAAF to the tension between fairness and inclusivity of bodies non-conforming to two sexes is not, however, the only possible solution/resolution to the case, as I aim to show in this paper. Here I present some reflections on this topic and suggest how CAS should approach the case if it hopes to resolve it.
机译:许多运动中存在根本紧张:人类性不是二元,但只有两类人们可以竞争:男女。在过去的10年里,国际田径联合会(IAAF)法规的协会一直处于两个值得注意的法律纠纷的中心。体育仲裁法院(CAS)达到了两个矛盾的裁决:在第一个案件(津贴Chand vs田径联合会印度和IAAF)中,暂停了竞选运动员竞争的竞争资格的IAAF条例(2015年7月24日)基于“对女性类别的歧视”;在后者(Caster Openenya和Artlics South Africa VS IAAF)中,重申了法规(2019年5月1日),虽然歧视性,但它们是保持“水平竞争领域”并“保护”女性类别。虽然Semenya的案例已经为质疑现有的运动中的性别规范铺平了途径,但尚未从她的案例中展出一个新的稳定规范。然而,由于我的目标是在本文中展示的情况下,由IAAF向公平和含有的身体的公平和包容性之间提出的药物和包容性之间唯一可能的解决方案/解决方案。在这里,我对此主题提出了一些思考,并建议如果它希望解决它,CAS应该如何接近这种情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号